)
Visual
test
Double Bond Pharmaceutical
Double Bond Pharmaceutical (DBP) investor relations material
Double Bond Pharmaceutical Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary26 Feb, 2026
Executive summary
2025 marked a breakthrough year with significant progress in SI053/Temodex development, focusing on glioblastoma treatment and expanding clinical applications to recurrent GBM.
Strategic collaborations and promising clinical data have strengthened confidence in the product's market potential.
Efforts are underway to commercialize Temodex outside Eastern Europe and integrate AI tools in research.
Financial highlights
Total group revenues for 2025 were SEK 0.1 million, down from SEK 1.1 million year-over-year.
Operating loss for the year was SEK -1.7 million, compared to SEK -1.6 million in 2024.
Net result for the year improved to SEK -0.3 million from SEK -7.1 million year-over-year.
Earnings per share for 2025 were SEK -0.0, compared to SEK -0.06 in 2024.
Cash and cash equivalents at year-end were SEK 1.1 million, down from SEK 3.9 million at the end of 2024.
Outlook and guidance
Existing liquidity and proceeds from the recent share issue are expected to fund operations through Q4 2026.
Future financing is anticipated from EU grants, product licensing, and potential new share issues.
No dividend is proposed for 2025, with ambitions to provide dividends in the future.
Temodex commercialization strategy outside Eastern Europe?
Update on licensing negotiations for future funding?
Quantify increased market potential from rGBM?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Double Bond Pharmaceutical
- Improved results and restored equity as S1053 advances toward potential partnerships.DBP
Q3 202514 Nov 2025 - Revenue and net loss improved, with strong project progress and a major rights issue launched.DBPQ2 202526 Aug 2025
- SI-053 clinical trial preparations advanced, with improved results and new financing secured.DBPQ3 202413 Jun 2025
- SI-053 clinical progress and new partnerships drive Double Bond Pharmaceutical's strategic focus.DBPQ2 202413 Jun 2025
- Revenues rose and losses narrowed as SI053 clinical trial preparations were completed.DBPQ1 20256 Jun 2025
- Losses narrowed as SI-053 advanced; funding secured, liquidity sufficient into Q3 2025.DBPQ4 20246 Jun 2025
Next Double Bond Pharmaceutical earnings date
Q1 202622 May, 2026
Double Bond Pharmaceutical
Next Double Bond Pharmaceutical earnings date
Q1 202622 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage